Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study

Table 1 Patient baseline characteristics

Characteristic	Count (%)
Male	59 (59.00)
Age	58.48 ± 13.90
Etiology
Hepatitis B related CLD	38 (38.00)
Hepatitis C related CLD	3 (3.00)
Schistosome related CLD	16 (16.00)
Autoimmune liver disease	14 (14.00)
Alcoholic liver disease	5 (5.00)
Liver tumors	14 (14.00)
Drug induced CLD	2 (2.00)
Liver abscess	1 (1.00)
Chronic liver failure	1 (1.00)
Budd Chiari syndrome	1 (1.00)
CLD of unknown origin	5 (5.00)
Child-Pugh grades
Grade A (5-6 points)	8 (8.00)
Grade B (7-9 points)	48 (48.00)
Grade C (10-15 points)	44 (44.00)
Different platelet counts (× 109/L)
Group I (< 30)	25 (25.00)
Group II (30-50)	43 (43.00)
Group III (> 50)	32 (32.00)
Medication duration
Group A ( 7 d)	31 (31.00)
Group B (8-14 d)	38 (38.00)
Group C (15-21 d)	22 (22.00)
Group D (22-28 d)	9 (9.00)
No platelet transfusion	90 (90.00)
Side effect
Fever	2 (2.00)
Fatigue and anorexia	4 (4.00)

CLD: Chronic liver disease.

Table 2 Changes in routine blood test results of the total population from baseline to post-treatment

	Baseline	Post-treatment	Change	95%CI	P value3
PLT (× 109/L)	42.88 ± 16.72	101.53 ± 81.81	58.65 ± 79.24	42.93, 74.37	< 0.001
PCT (%)	0.05 ± 0.02	0.14 ± 0.10	0.08 ± 0.091	0.06, 0.11	< 0.001
MPV (fL)	11.61 ± 1.48	11.76 ± 1.26	0.14 ± 1.502	-0.27, 0.55	0.498
PDW (%)	16.01 ± 2.55	15.16 ± 3.09	-0.77 ± 3.992	-1.85, 0.32	0.162

¹Data were analyzed in 58 patients.

²This was an analysis of 54 patients.

³Paired sample t-test.

PLT: Platelet count; PCT: Platelet crit; MPV: Platelet volume; PDW: Platelet distribution width.

Table 3 Comparison of platelet counts at baseline and post-treatment in the different platelet count groups

	Baseline (× 109/L)	Post-treatment (× 109/L)	Change (× 109/L)	P value1
Group I (n = 25)				< 0.001
mean ± SD	21.60 ± 7.22	68.28 ± 57.52	46.68 ± 56.77
Median	21.00	55.00	35.00
IQR	16.50-28.00	30.50-82.50	4.50-56.50
Min, max	6.00, 30.00	7.00, 235.00	-4.00, 214.00
Group II (n = 43)				< 0.001
mean ± SD	41.19 ± 5.81	96.23 ± 80.58	55.05 ± 79.80
Median	41.00	76.00	35.00
IQR	35.00-46.00	54.00-133.00	12.00-93.00
Min, max	31.00, 50.00	9.00, 489.00	-31.00, 448.00
Group III (n = 32)				< 0.001
mean ± SD	61.78 ± 8.28	141.53 ± 86.99	79.75 ± 87.04
Median	61.00	127.50	70.00
IQR	55.00-67.00	53.25-214.25	-4.75-146.50
Min, max	51.00, 86.00	7.00, 307.00	-53.00, 255.00

¹Wilcoxon rank sum test.

Table 4 Comparison of platelet crit at baseline and post-treatment in the different platelet count groups

	Baseline (%)	Post-treatment (%)	Change (%)	P value1
Group I (n = 25)				0.0182
mean ± SD	0.02 ± 0.01	0.08 ± 0.06	0.06 ± 0.05
Median	0.02	0.08	0.05
IQR	0.01-0.03	0.02-0.12	0.01-0.10
Min, max	0.01, 0.03	0.01, 0.18	0.00, 0.15
Group II (n = 43)				< 0.0013
mean ± SD	0.05 ± 0.04	0.13 ± 0.09	0.08 ± 0.11
Median	0.05	0.09	0.05
IQR	0.04-0.05	0.07-0.16	0.03-0.11
Min, max	0.03, 0.26	0.01, 0.51	-0.19, 0.46
Group III (n = 32)				< 0.0014
mean ± SD	0.07 ± 0.01	0.17 ± 0.09	0.10± 0.10
Median	0.07	0.17	0.07
IQR	0.06-0.08	0.09-0.25	0.01-0.18
Min, max	0.05, 0.09	0.04, 0.36	-0.04, 0.29

¹Wilcoxon rank sum test.

²Data were analyzed by 8 patients.

³PThis was an analysis of 31 patients.

⁴Date were analyzed by 19 patients.

Table 5 Comparison of platelet counts at baseline and post-treatment in patients with different Child-Pugh grades

	Baseline (× 109/L)	Post-treatment (× 109/L)	Change (× 109/L)
Child-Pugh A (n = 8)
mean ± SD	41.75 ± 21.68	53.63 ± 34.13	11.88 ± 33.00
Median	47.00	48.50	3.00
IQR	23.00-55.75	39.25-62.25	-6.00-38.50
Min, max	6.00, 73.00	7.00, 127.00	-34.00, 71.00
Child-Pugh B (n = 48)
mean ± SD	44.08 ± 17.01	105.88 ± 73.34	61.79 ± 69.53
Median	46.50	82.00	50.50
IQR	30.00-55.75	49.25-175.00	5.00-124.75
Min, max	10.00, 80.00	7.00, 266.00	-53.00, 214.00
Child-Pugh C (n = 44)
mean ± SD	42.00 ± 16.36	105.52 ± 94.30	63.52 ± 91.48
Median	40.50	72.50	37.50
IQR	33.25-51.75	47.00-139.75	6.25-104.00
Min, max	9.00, 86.00	15.00, 489.00	-36.00, 448.00

Table 6 Changes in platelet counts in group A (7 d of treatment)

	Baseline	Day 2	Day 5	Post-treatment	Change
n	31	10	26	31	31
mean ± SD (× 109/L)	41.87 ± 17.40	42.90 ± 29.41	42.04 ± 27.39	67.74 ± 62.81	25.87 ± 57.67
Median (× 109/L)	45.00	41.50	42.00	54.00	10.00
IQR (× 109/L)	33.00-55.00	17.25-54.00	19.75-54.25	28.00-80.00	-7.00-44.00
Min, max (× 109/L)	6.00, 73.00	15.00,111.00	9.00, 127.00	7.00, 303.00	-34.00, 244.00

Table 7 Changes in platelet counts in group B (8-14 d of treatment)

	Baseline	Day 2	Day 5	Day 9	Post-treatment	Change
n	38	20	29	26	38	38
mean ± SD (× 109/L)	45.42 ± 16.27	46.10 ± 14.34	60.79 ± 33.18	108.19 ± 65.18	133.85 ± 103.23	81.97 ± 90.29
Median (× 109/L)	43.00	43.50	55.00	96.00	95.00	55.00
IQR (× 109/L)	33.50-55.50	33.75-57.75	37.00-70.00	49.00-166.75	58.00-190.00	21.25-127.25
Min, max (× 109/L)	9.00, 80.00	25.00, 71.00	18.00, 170.00	28.00, 261.00	21.00, 489.00	-27.00, 448.00

Table 8 Changes in platelet counts in group C (15-21 d of treatment)

	Baseline	Day 5	Day 9	Day 14	Post-treatment	Change
n	22	17	18	18	22	22
mean ± SD (× 109/L)	43.36 ± 19.23	47.47 ± 19.60	69.50 ± 33.25	107.61 ± 65.53	106.32 ± 65.97	62.95 ± 64.96
Median (× 109/L)	45.00	51.00	78.50	92.50	90.50	47.50
IQR (× 109/L)	27.75-59.25	31.00-54.50	32.50-85.75	55.25-181.25	55.25-148.00	16.5-128.25
Min, max (× 109/L)	10.00, 86.00	19.00, 95.00	20.00, 138.00	7.00, 235.00	7.00, 222.00	-53.00, 179.00

Table 9 Changes in platelet counts in group D (22-28 d of treatment)

	Baseline	Day 5	Day 14	Day 24	Post-treatment	Change
n	9	9	7	8	9	9
mean ± SD (× 109/L)	35.56 ± 11.72	41.22 ± 17.41	50.29 ± 33.76	83.88 ± 34.87	90.89 ± 71.85	55.33 ± 63.15
Median (× 109/L)	34.00	37.00	42.00	84.50	79.00	45.00
IQR (× 109/L)	27.50-38.00	33.00-51.50	39.00-45.00	47.75-118.00	36.50-126.50	5.50-93.00
Min, max (× 109/L)	25.00, 64.00	16.00, 78.00	18.00, 124.00	42.00, 127.00	29.00, 254.00	-12.00, 190.00